Latest News & Updates

FDA approves darolutamide for metastatic castration-sensitive prostate cancer
June 3, 2025

Continue Reading »

A Phase 3 Study of elacestrant versus standard endocrine therapy in node-positive ER+, HER2- early breast cancer with high risk of recurrence (ELEGANT)
November 22, 2024

Continue Reading »

Applications Are Open for the ASCO Quality Training Program (QTP)
October 25, 2024

Continue Reading »

Merit-based Incentive Payment System (MIPS) Automatic Extreme and Uncontrollable Circumstances (EUC) Policy Applied to MIPS Eligible Clinicians Following Hurricanes Helene and Francine
October 25, 2024

Continue Reading »

FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
June 18, 2025

Continue Reading »

FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma
June 15, 2025

Continue Reading »

FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal
May 16, 2025

Continue Reading »

FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression
May 15, 2025

Continue Reading »

Get More from FLASCO With Your Partnership

The Corporate Partnership Program allows FLASCO to expand our offerings to our partners. Every FLASCO meeting also provides the industry representative with opportunities to educate our partners. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Partners

Presidential

Elite

Diamond

Platinum

Gold

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: